乳がん術前・術後化学療法としてのアントラサイクリン／シクロホスファミド併用療法に対する予防的制吐療法におけるアプレピタントおよびデキサメタゾンの有効性および安全性
「緒言」乳がん術前・術後におけるアントラサイクリン/シクロホスファミド併用療法(ドキソルビシン60mg/m2/シクロホスファミド600mg/m2併用療法:AC療法, シクロホスファミド500mg/m2/エピルビシン100mg/m2/フルオロウラシル500mg/m2併用療法:CEF療法)による主な有害事象の1つに, 悪心・嘔吐が挙げられる. 患者のquality of life(QOL)や治療強度を保つためには, 悪心・嘔吐を最小限に抑えることが極めて重要である. AC, CEF療法に対する予防的制吐療法についてはこれまでに多数の報告がなされている. 2報の二重盲検ランダム化比較試験において,...
Saved in:
| Published in | 医療薬学 Vol. 41; no. 9; pp. 603 - 611 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | Japanese |
| Published |
一般社団法人日本医療薬学会
10.09.2015
日本医療薬学会 |
| Online Access | Get full text |
| ISSN | 1346-342X 1882-1499 |
| DOI | 10.5649/jjphcs.41.603 |
Cover
| Abstract | 「緒言」乳がん術前・術後におけるアントラサイクリン/シクロホスファミド併用療法(ドキソルビシン60mg/m2/シクロホスファミド600mg/m2併用療法:AC療法, シクロホスファミド500mg/m2/エピルビシン100mg/m2/フルオロウラシル500mg/m2併用療法:CEF療法)による主な有害事象の1つに, 悪心・嘔吐が挙げられる. 患者のquality of life(QOL)や治療強度を保つためには, 悪心・嘔吐を最小限に抑えることが極めて重要である. AC, CEF療法に対する予防的制吐療法についてはこれまでに多数の報告がなされている. 2報の二重盲検ランダム化比較試験において, AC, CEF療法に対し, デキサメタゾン(dexamethasone:DEX), 5-HT3受容体拮抗薬の2剤併用群と比較し, アプレピタント(aprepitant:APR)を追加した3剤併用群で制吐効果の優越性が示されている. |
|---|---|
| AbstractList | 「緒言」乳がん術前・術後におけるアントラサイクリン/シクロホスファミド併用療法(ドキソルビシン60mg/m2/シクロホスファミド600mg/m2併用療法:AC療法, シクロホスファミド500mg/m2/エピルビシン100mg/m2/フルオロウラシル500mg/m2併用療法:CEF療法)による主な有害事象の1つに, 悪心・嘔吐が挙げられる. 患者のquality of life(QOL)や治療強度を保つためには, 悪心・嘔吐を最小限に抑えることが極めて重要である. AC, CEF療法に対する予防的制吐療法についてはこれまでに多数の報告がなされている. 2報の二重盲検ランダム化比較試験において, AC, CEF療法に対し, デキサメタゾン(dexamethasone:DEX), 5-HT3受容体拮抗薬の2剤併用群と比較し, アプレピタント(aprepitant:APR)を追加した3剤併用群で制吐効果の優越性が示されている. |
| Author | 原島, 寿江 原, 茉梨絵 中島, 寿久 牧野, 好倫 藤原, 康弘 田村, 研治 清水, 千佳子 温泉川, 真由 文, 靖子 岩瀬, 治雄 田辺, 裕子 公平, 誠 林, 憲一 山本, 春風 橋本, 淳 龍島, 靖明 |
| Author_xml | – sequence: 1 fullname: 林, 憲一 organization: 国立がん研究センター中央病院 薬剤部 – sequence: 1 fullname: 公平, 誠 organization: 国立がん研究センター中央病院 乳腺・腫瘍内科 – sequence: 1 fullname: 藤原, 康弘 organization: 国立がん研究センター中央病院 乳腺・腫瘍内科 – sequence: 1 fullname: 田村, 研治 organization: 国立がん研究センター中央病院 乳腺・腫瘍内科 – sequence: 1 fullname: 橋本, 淳 organization: 国立がん研究センター中央病院 乳腺・腫瘍内科 – sequence: 1 fullname: 文, 靖子 organization: 国立がん研究センター中央病院 薬剤部 – sequence: 1 fullname: 原島, 寿江 organization: 国立がん研究センター中央病院 薬剤部 – sequence: 1 fullname: 中島, 寿久 organization: 国立がん研究センター中央病院 薬剤部 – sequence: 1 fullname: 岩瀬, 治雄 organization: 国立がん研究センター中央病院 薬剤部 – sequence: 1 fullname: 原, 茉梨絵 organization: 国立がん研究センター中央病院 薬剤部 – sequence: 1 fullname: 牧野, 好倫 organization: 国立がん研究センター中央病院 薬剤部 – sequence: 1 fullname: 温泉川, 真由 organization: 国立がん研究センター中央病院 乳腺・腫瘍内科 – sequence: 1 fullname: 山本, 春風 organization: 国立がん研究センター中央病院 乳腺・腫瘍内科 – sequence: 1 fullname: 田辺, 裕子 organization: 国立がん研究センター中央病院 乳腺・腫瘍内科 – sequence: 1 fullname: 龍島, 靖明 organization: 国立がん研究センター中央病院 薬剤部 – sequence: 1 fullname: 清水, 千佳子 organization: 国立がん研究センター中央病院 乳腺・腫瘍内科 |
| BookMark | eNo9UU1v00AQtVCRKKVHfobDrr3e2DdQBQWpEheQuK3stUNtJU5klwM3vAsiKUEUtaUUkFAQKuEjqURUUPgIP2biBE4c-AOs04_LzJuZN--tds5qc3E9DjTtPEYlixLnQhQ1VnlaIrhEkXlKm8e2beiYOM6cwiahukmMW2e0xTQNPYRMjCm2nHnt33g4gKwNYvN3ZzNvPQb5vQCjdt5-lvf2prtiMtiGrAvZDmR7kPVBvAE5ANkE-R7EAYi3IPZBflDNvz-egPg6K3sgX4IYgtwG0QH5GmRr_PNgutU9FvyY748g2wXxaPyt-ef55-mL-3nzS76xcUKAbB2yp4owc9wB-QnkFohfR-5qKlRU-CGIXvES2SmmYlQQsv7kVStfH07uvTth5v1W_qCrOue00xW3mgaLR3lBu3nl8o2lq_rK9eVrS5dW9MjEBtJNn7gmp6bnEUo5srnChm8jbnNa9iplJ7ANTCsODhy_THgZqdLl2FAfHXg2JuaCtnyoWwv8kLvVelwN44BF9TtJrHyZ71mNVTepMQNhiyFEMHJUwgypE6qAsWEhm1KslC4eKkXpmns7YI0krLnJXeYmayGvKsnZ8RnBzClCsX484sqBRa75H99q_3s |
| ContentType | Journal Article |
| Copyright | 2015 日本医療薬学会 |
| Copyright_xml | – notice: 2015 日本医療薬学会 |
| CorporateAuthor | 国立がん研究センター中央病院 乳腺・腫瘍内科 国立がん研究センター中央病院 薬剤部 |
| CorporateAuthor_xml | – name: 国立がん研究センター中央病院 乳腺・腫瘍内科 – name: 国立がん研究センター中央病院 薬剤部 |
| DOI | 10.5649/jjphcs.41.603 |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1882-1499 |
| EndPage | 611 |
| ExternalDocumentID | db5pharm_2015_004109_001_0603_06112508661 article_jjphcs_41_9_41_603_article_char_ja |
| GroupedDBID | .LE 5GY ABJNI ALMA_UNASSIGNED_HOLDINGS KQ8 MOJWN RJT |
| ID | FETCH-LOGICAL-j3120-3d4a3c63bb466c08cc632d80c8c67bf79e8216f91e9d74c70821ac12342eb8143 |
| ISSN | 1346-342X |
| IngestDate | Thu Jul 10 16:14:13 EDT 2025 Wed Sep 03 06:15:56 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 9 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j3120-3d4a3c63bb466c08cc632d80c8c67bf79e8216f91e9d74c70821ac12342eb8143 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/jjphcs/41/9/41_603/_article/-char/ja |
| PageCount | 9 |
| ParticipantIDs | medicalonline_journals_db5pharm_2015_004109_001_0603_06112508661 jstage_primary_article_jjphcs_41_9_41_603_article_char_ja |
| PublicationCentury | 2000 |
| PublicationDate | 20150910 |
| PublicationDateYYYYMMDD | 2015-09-10 |
| PublicationDate_xml | – month: 09 year: 2015 text: 20150910 day: 10 |
| PublicationDecade | 2010 |
| PublicationTitle | 医療薬学 |
| PublicationTitleAlternate | 医療薬学 |
| PublicationYear | 2015 |
| Publisher | 一般社団法人日本医療薬学会 日本医療薬学会 |
| Publisher_xml | – name: 一般社団法人日本医療薬学会 – name: 日本医療薬学会 |
| References | 18) Roila F, Ruggeri B, Ballatori E, Del Favero A, Tonato M, Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study, J Clin Oncol, 2014, 32, 101-106. 25) Ioannidis JP, Hesketh PJ, Lau J, Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence, J Clin Oncol, 2000, 18, 3409-3422. 14) Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ, The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group, J Clin Oncol, 2003, 21, 4112-4119. 22) Young SN, Mechanism of decline in rat brain 5-hydroxytryptamine after induction of liver tryptophan pyrrolase by hydrocortisone: roles of tryptophan catabolism and kynurenine synthesis, Br J Pharmacol, 1981, 74, 695-700. 2) Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T, Schmoll HJ, Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study, Support Care Cancer, 2010, 18, 423-431. 5）日本癌治療学会編集, “制吐薬適正使用ガイドライン”, 第1版, 金原出版株式会社, 東京, 2010, pp12-46. 13) Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ, Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy induced nausea and vomiting, Cancer, 2003, 97, 2290-2300. 12) Multinational Association of Supportive Care in Cancer, MASCC / ESMO Antiemetic Guideline 2011. 11) Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D, Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomitings: results of the Perugia consensus conference, Ann Oncol, 2010, 21, 232-243. 10) Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH, Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update, J Clin Oncol, 2011, 29, 4189-4198. 1) Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F, Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy, J Clin Oncol, 2005, 23, 2822-2830. 7) National Comprehensive Cancer Network, NCCN Clinical Practice Guideline in Oncology: Guidelines for Supportive Care Antiemesis, version 2, 2010. 21) Naylor RJ, Rudd JA, Mechanisms of chemotherapy/radiotherapy-induced emesis in animal models, Oncology, 1996, 53 Suppl 1, 8-17. 19) Aapro M, Fabi A, Nolè F, Medici M, Steger G, Bachmann C, Roncoroni S, Roila F, Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy, Ann Oncol, 2010, 21, 1083-1088. 17) Tonato M, Roila F, Del Favero A, Methodology of antiemetic trials: a review, Ann Oncol, 1991, 2, 107-114. 23) McCrea JB, Majumdar AK, Goldberg MR, Iwamoto M, Gargano C, Panebianco DL, Hesney M, Lines CR, Petty KJ, Deutsch PJ, Murphy MG, Gottesdiener KM, Goldwater DR, Blum RA, Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone, Clin Pharmacol Ther, 2003, 74, 17-24. 8) National Comprehensive Cancer Network, NCCN Clinical Practice Guideline in Oncology: Guidelines for Supportive Care Antiemesis, version 2, 2014. 27）斉藤麻美, 伊達祐子, 江頭伸昭, 辰島瑶子, 村上裕子, 三嶋一登, 小林裕明, 大石了三, がん化学療法で使用するデキサメタゾンの糖尿病合併がん患者の血糖値に及ぼす影響, 日本病院薬剤師会雑誌, 2011, 47, 1261-1264. 15) Koo WH, Ang PT, Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy, Ann Oncol, 1996, 7, 71-74. 3) Meattini I, Francolini G, Scotti V, De Luca Cardillo C, Cappelli S, Meacci F, Furfaro IF, Muntoni C, Scoccianti S, Detti B, Mangoni M, Nori J, Orzalesi L, Fambrini M, Bianchi S, Livi L, Aprepitant as prophylaxis of chemotherapy-induced nausea and vomiting in anthracyclines and cyclophosphamide-based regimen for adjuvant breast cancer, Med Oncol, 2015, 32, 80-84. 6) National Comprehensive Cancer Network, NCCN Clinical Practice Guideline in Oncology: Guidelines for Supportive Care Antiemesis, version 1, 2005. 9) Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM, American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006, J Clin Oncol, 2006, 24, 2932-2947. 4）田頭尚士, 松久哲章, 尾瀬 功, 清藤佐知子, 高橋三奈, 原 文堅, 高畠大典, 高嶋成輝, 青儀健二郎, 大住省三, 江口久恵, 乳癌患者に対するアプレピタントの有効性および安全性の検討, 癌と化学療法, 2011, 38, 1307-1311. 16) Italian Group For Antiemetic Research, Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide, J Clin Oncol, 2004, 22, 725-729. 20）佃 守, がん化学療法時の悪心・嘔吐のメカニズムと最新の制吐剤, 臨床腫瘍プラクティス, 2010, 6, 92-98. 24) Takahashi T, Nakamura Y, Tsuya A, Murakami H, Endo M, Yamamoto N, Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients, Cancer Chemother Pharmacol, 2011, 68, 653-659. 26）久保田豊, 三原 潔, 石井文由, 大野恵子, 緒方宏泰, 牧村瑞恵, 菊池憲和, 北野妙子, シスプラチンによる遅延性悪心・嘔吐に対する薬物療法の検討：システマティック・レビュー, YAKUGAKU ZASSHI, 2004, 124, 1-11. |
| References_xml | – reference: 4）田頭尚士, 松久哲章, 尾瀬 功, 清藤佐知子, 高橋三奈, 原 文堅, 高畠大典, 高嶋成輝, 青儀健二郎, 大住省三, 江口久恵, 乳癌患者に対するアプレピタントの有効性および安全性の検討, 癌と化学療法, 2011, 38, 1307-1311. – reference: 22) Young SN, Mechanism of decline in rat brain 5-hydroxytryptamine after induction of liver tryptophan pyrrolase by hydrocortisone: roles of tryptophan catabolism and kynurenine synthesis, Br J Pharmacol, 1981, 74, 695-700. – reference: 5）日本癌治療学会編集, “制吐薬適正使用ガイドライン”, 第1版, 金原出版株式会社, 東京, 2010, pp12-46. – reference: 18) Roila F, Ruggeri B, Ballatori E, Del Favero A, Tonato M, Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study, J Clin Oncol, 2014, 32, 101-106. – reference: 25) Ioannidis JP, Hesketh PJ, Lau J, Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence, J Clin Oncol, 2000, 18, 3409-3422. – reference: 16) Italian Group For Antiemetic Research, Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide, J Clin Oncol, 2004, 22, 725-729. – reference: 3) Meattini I, Francolini G, Scotti V, De Luca Cardillo C, Cappelli S, Meacci F, Furfaro IF, Muntoni C, Scoccianti S, Detti B, Mangoni M, Nori J, Orzalesi L, Fambrini M, Bianchi S, Livi L, Aprepitant as prophylaxis of chemotherapy-induced nausea and vomiting in anthracyclines and cyclophosphamide-based regimen for adjuvant breast cancer, Med Oncol, 2015, 32, 80-84. – reference: 6) National Comprehensive Cancer Network, NCCN Clinical Practice Guideline in Oncology: Guidelines for Supportive Care Antiemesis, version 1, 2005. – reference: 12) Multinational Association of Supportive Care in Cancer, MASCC / ESMO Antiemetic Guideline 2011. – reference: 9) Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM, American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006, J Clin Oncol, 2006, 24, 2932-2947. – reference: 13) Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ, Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy induced nausea and vomiting, Cancer, 2003, 97, 2290-2300. – reference: 7) National Comprehensive Cancer Network, NCCN Clinical Practice Guideline in Oncology: Guidelines for Supportive Care Antiemesis, version 2, 2010. – reference: 15) Koo WH, Ang PT, Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy, Ann Oncol, 1996, 7, 71-74. – reference: 24) Takahashi T, Nakamura Y, Tsuya A, Murakami H, Endo M, Yamamoto N, Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients, Cancer Chemother Pharmacol, 2011, 68, 653-659. – reference: 23) McCrea JB, Majumdar AK, Goldberg MR, Iwamoto M, Gargano C, Panebianco DL, Hesney M, Lines CR, Petty KJ, Deutsch PJ, Murphy MG, Gottesdiener KM, Goldwater DR, Blum RA, Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone, Clin Pharmacol Ther, 2003, 74, 17-24. – reference: 2) Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T, Schmoll HJ, Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study, Support Care Cancer, 2010, 18, 423-431. – reference: 8) National Comprehensive Cancer Network, NCCN Clinical Practice Guideline in Oncology: Guidelines for Supportive Care Antiemesis, version 2, 2014. – reference: 19) Aapro M, Fabi A, Nolè F, Medici M, Steger G, Bachmann C, Roncoroni S, Roila F, Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy, Ann Oncol, 2010, 21, 1083-1088. – reference: 1) Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F, Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy, J Clin Oncol, 2005, 23, 2822-2830. – reference: 27）斉藤麻美, 伊達祐子, 江頭伸昭, 辰島瑶子, 村上裕子, 三嶋一登, 小林裕明, 大石了三, がん化学療法で使用するデキサメタゾンの糖尿病合併がん患者の血糖値に及ぼす影響, 日本病院薬剤師会雑誌, 2011, 47, 1261-1264. – reference: 10) Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH, Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update, J Clin Oncol, 2011, 29, 4189-4198. – reference: 11) Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D, Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomitings: results of the Perugia consensus conference, Ann Oncol, 2010, 21, 232-243. – reference: 14) Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ, The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group, J Clin Oncol, 2003, 21, 4112-4119. – reference: 17) Tonato M, Roila F, Del Favero A, Methodology of antiemetic trials: a review, Ann Oncol, 1991, 2, 107-114. – reference: 20）佃 守, がん化学療法時の悪心・嘔吐のメカニズムと最新の制吐剤, 臨床腫瘍プラクティス, 2010, 6, 92-98. – reference: 26）久保田豊, 三原 潔, 石井文由, 大野恵子, 緒方宏泰, 牧村瑞恵, 菊池憲和, 北野妙子, シスプラチンによる遅延性悪心・嘔吐に対する薬物療法の検討：システマティック・レビュー, YAKUGAKU ZASSHI, 2004, 124, 1-11. – reference: 21) Naylor RJ, Rudd JA, Mechanisms of chemotherapy/radiotherapy-induced emesis in animal models, Oncology, 1996, 53 Suppl 1, 8-17. |
| SSID | ssib003116159 ssib002484604 ssib000871962 ssib060196744 ssj0069027 ssib005902156 ssib023157658 |
| Score | 2.0354419 |
| Snippet | 「緒言」乳がん術前・術後におけるアントラサイクリン/シクロホスファミド併用療法(ドキソルビシン60mg/m2/シクロホスファミド600mg/m2併用療法:AC療法, シクロホスファミド500mg/m2/エピルビシン100mg/m2/フルオロウラシル500mg/m2併用療法:CEF療法)による主な有害事象の1つに,... |
| SourceID | medicalonline jstage |
| SourceType | Publisher |
| StartPage | 603 |
| Title | 乳がん術前・術後化学療法としてのアントラサイクリン／シクロホスファミド併用療法に対する予防的制吐療法におけるアプレピタントおよびデキサメタゾンの有効性および安全性 |
| URI | https://www.jstage.jst.go.jp/article/jjphcs/41/9/41_603/_article/-char/ja http://mol.medicalonline.jp/library/journal/download?GoodsID=db5pharm/2015/004109/001&name=0603-0611j |
| Volume | 41 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | 医療薬学, 2015/09/10, Vol.41(9), pp.603-611 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR1Nb9xE1KraCxJCfIqWUu0B99RN1_bMeOaGvR-qkEBFSqXcrLWzK7QSbUTSQzlhG0TSplJRW0oBCQWhEj6SSkQFBUT4MRMn5cg_4L3xjO2lHwrtZfT2zZs38z48nuedeWNZb9DOWLidmLRjl9M2cWLWFj6N2_AqHSceJmxTx6PffoedOUfemqNzh45caexaurgUzyQfPvRcyZNYFXBgVzwl-z8sWzEFBMBgXyjBwlAeyMZ2n9ihsEPP7nuwJLR5VwGuLQDD7cBRALW5sHlPVXl2GE5VhX3VimIpGAJBzw4A8G0hkFWfIX9BdRcB14DwDYYZoK97D1zTl6cBzjUQCE0TUkNMDDAwNEHd3B0Yev8BMiORCA2NMJiKuWMwphWoApXWUwMAGYmS6FHChkohA9SSltqMn4eKT6BEE7bgdugqPoAhSp-AUfoUuJXksV2UtgtMF06ji2l9ap2D7F2DMdoLB4_QecXZrTE1TaXV3rRdPKO6irNrlODV_oYWZ7boKq1S7AhNwHD3TOA_tneKbXUrqkygWzWDJe2W6LGV9jh6adCtHNVMGIq2r-zMsRFXAwHNleYFsUJa04LluJKZ4mhKO6GZB_qJ4vQhfB-kBVOCvQY1rVDPU5MvuEZPPVgMfYT3m1_ZHIpbgvR-a5wXFZVvB1SrNegeRAVqzPD0Bo0FhkdY2yPuXHMFUqZ-0zOtaCwnWMdrrExZuSz576KHMoI5gyeThfeSxRnizFStpvLIz8d0AbPhRyhehHn2OgJ3tEYdoIcCAi8I1hh-Sjri-hCI4A6Xd5uxmg9v60auQQeDxUbuP4HhQxXbQNxI_UZiKYaJuNRVG-UymQG5uvnKKKRMgIzCnJ4SBUKDCQTKmAHl2ffLP6_LJEKNOGD2ees5HcC3gnI2fsE6NBm-aJ08W94AcOlUa7Y-0Lp4qnWydba-G-DSS9Y_u9tbMl2V2fX7a9eLlasy_wOBndVi9fNi487-7Wxv66ZM12V6S6Z3ZLops29lviXzZZn_ILN7MvtOZndl_iMgT8vsN_VjQ-ZfyWxb5jdltibzb2S-svvnvf0b64bdT8XdHZneltmV3d-X__7il_0vPy6Wfy2uXasIZHpZpp8Bgervlsx_lvkNmf2l-4baDEqAP5XZBo4jX8PabAcJ0s29r1eKy9t7H31fURabK8Un64B52To36M92z7T1rTvtiedgOo15MvQS5sUxYSzp8ARgd553Ep4wPx77YsRdh42FMxLzPkl8iCGdYQIBEHFHMYfw-xXr8PkL50evWi2KXw9GY2eU0IRQNxmOxsNhLDzheRDVes5RS5SmjRbK1EqRfpVGpQdExIkEFuihpgpPI0eT4VHrzSlviPR7eTE6sKMfe3oWr1nP1LPFcevw0gcXR69DlLoUn1BPz7-MkKz1 |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E4%B9%B3%E3%81%8C%E3%82%93%E8%A1%93%E5%89%8D%E3%83%BB%E8%A1%93%E5%BE%8C%E5%8C%96%E5%AD%A6%E7%99%82%E6%B3%95%E3%81%A8%E3%81%97%E3%81%A6%E3%81%AE%E3%82%A2%E3%83%B3%E3%83%88%E3%83%A9%E3%82%B5%E3%82%A4%E3%82%AF%E3%83%AA%E3%83%B3%2F%E3%82%B7%E3%82%AF%E3%83%AD%E3%83%9B%E3%82%B9%E3%83%95%E3%82%A1%E3%83%9F%E3%83%89%E4%BD%B5%E7%94%A8%E7%99%82%E6%B3%95%E3%81%AB%E5%AF%BE%E3%81%99%E3%82%8B%E4%BA%88%E9%98%B2%E7%9A%84%E5%88%B6%E5%90%90%E7%99%82%E6%B3%95%E3%81%AB%E3%81%8A%E3%81%91%E3%82%8B%E3%82%A2%E3%83%97%E3%83%AC%E3%83%94%E3%82%BF%E3%83%B3%E3%83%88%E3%81%8A%E3%82%88%E3%81%B3%E3%83%87%E3%82%AD%E3%82%B5%E3%83%A1%E3%82%BF%E3%82%BE%E3%83%B3%E3%81%AE%E6%9C%89%E5%8A%B9%E6%80%A7%E3%81%8A%E3%82%88%E3%81%B3%E5%AE%89%E5%85%A8%E6%80%A7&rft.jtitle=%E5%8C%BB%E7%99%82%E8%96%AC%E5%AD%A6&rft.au=%E5%8E%9F%E8%8C%89%E6%A2%A8%E7%B5%B5&rft.au=%E4%B8%AD%E5%B3%B6%E5%AF%BF%E4%B9%85&rft.au=%E5%8E%9F%E5%B3%B6%E5%AF%BF%E6%B1%9F&rft.au=%E9%BE%8D%E5%B3%B6%E9%9D%96%E6%98%8E&rft.date=2015-09-10&rft.pub=%E6%97%A5%E6%9C%AC%E5%8C%BB%E7%99%82%E8%96%AC%E5%AD%A6%E4%BC%9A&rft.issn=1346-342X&rft.volume=41&rft.issue=9&rft.spage=603&rft.epage=611&rft_id=info:doi/10.5649%2Fjjphcs.41.603&rft.externalDocID=db5pharm_2015_004109_001_0603_06112508661 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1346-342X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1346-342X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1346-342X&client=summon |